Literature DB >> 20439591

Serial measurements of lung function in a cohort of young children with bronchopulmonary dysplasia.

Khoulood F Fakhoury1, Charles Sellers, E O'Brian Smith, Jennifer A Rama, Leland L Fan.   

Abstract

OBJECTIVE: We aimed to prospectively and longitudinally measure lung function in a cohort of children with bronchopulmonary dysplasia (BPD) during their first 3 years of life.
METHODS: Forty-four children with BPD with a mean (+ or - SD) gestational age of 25.6 (+ or - 1.7) weeks and birth weight of 0.767 (+ or - 0.2) kg underwent serial measurements of lung function (maximum flow at functional residual capacity [V(max)FRC] and functional residual capacity [FRC]) at 6, 12, and 24 months after initial discharge from the neonatal care unit.
RESULTS: Compared with normative data, children with BPD had low partial expiratory airflow, measured by V(max)FRC, with mean z score (+ or - SD) of -1.92 (+ or - 1.04), -1.79 (+ or - 1.5), and -1.67 (+ or - 1.5) at 6, 12, and 24 months, respectively. Over time there was no significant improvement in z scores (P = .66), and 45% of the patients had a z score value of less than -2 (2 SDs below the mean) at the end of the study. FRC measurements steadily and significantly increased over time. Partial expiratory flow showed no correlation with gestational age, birth weight, or length of mechanical ventilation. Mean FRC was significantly higher in children who were using bronchodilators and inhaled steroids but showed no correlation with clinical symptoms. Bronchodilator response was initially present in 30% of the patients and declined to 20% at the end of the study.
CONCLUSIONS: During the first 3 years of life, children with mostly moderate-to-severe BPD continue to show significant abnormalities with airflow limitation according to lung-function testing.

Entities:  

Mesh:

Year:  2010        PMID: 20439591     DOI: 10.1542/peds.2009-0668

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  29 in total

Review 1.  Influence of infection during pregnancy on fetal development.

Authors:  Kristina M Adams Waldorf; Ryan M McAdams
Journal:  Reproduction       Date:  2013-10-01       Impact factor: 3.906

2.  [Dynamic observation of pulmonary function by plethysmography in preterm infants with bronchopulmonary dysplasia].

Authors:  Jing Zhang; Ling-Ping Zhang; Lan Kang; Xiao-Ping Lei; Wen-Bin Dong
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-12

Review 3.  Understanding the Short- and Long-Term Respiratory Outcomes of Prematurity and Bronchopulmonary Dysplasia.

Authors:  Jessica Y Islam; Roberta L Keller; Judy L Aschner; Tina V Hartert; Paul E Moore
Journal:  Am J Respir Crit Care Med       Date:  2015-07-15       Impact factor: 21.405

Review 4.  Assessment of inhibited alveolar-capillary membrane structural development and function in bronchopulmonary dysplasia.

Authors:  Shawn K Ahlfeld; Simon J Conway
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-03-06

Review 5.  The new bronchopulmonary dysplasia.

Authors:  Alan H Jobe
Journal:  Curr Opin Pediatr       Date:  2011-04       Impact factor: 2.856

6.  Perinatal factors in neonatal and pediatric lung diseases.

Authors:  Rodney D Britt; Arij Faksh; Elizabeth Vogel; Richard J Martin; Christina M Pabelick; Y S Prakash
Journal:  Expert Rev Respir Med       Date:  2013-10-03       Impact factor: 3.772

Review 7.  Trajectories of Lung Function in Infants and Children: Setting a Course for Lifelong Lung Health.

Authors:  Brian K Jordan; Cindy T McEvoy
Journal:  Pediatrics       Date:  2020-09-16       Impact factor: 7.124

Review 8.  Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment.

Authors:  Jung S Hwang; Virender K Rehan
Journal:  Lung       Date:  2018-01-27       Impact factor: 2.584

Review 9.  The Natural History of Bronchopulmonary Dysplasia: The Case for Primary Prevention.

Authors:  Cindy T McEvoy; Judy L Aschner
Journal:  Clin Perinatol       Date:  2015-10-01       Impact factor: 3.430

10.  Neonatal therapy with PF543, a sphingosine kinase 1 inhibitor, ameliorates hyperoxia-induced airway remodeling in a murine model of bronchopulmonary dysplasia.

Authors:  Alison W Ha; Tara Sudhadevi; David L Ebenezer; Panfeng Fu; Evgeny V Berdyshev; Steven J Ackerman; Viswanathan Natarajan; Anantha Harijith
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-07-22       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.